Firms
Theme

NGVT

Ingevity Corporation · NYSE

News

4 latest

Zacks Investment Research

Is NGVT Positioned for Further Adjusted EBITDA Improvement?

Ingevity Corporation (NGVT) reported Q2 adjusted EBITDA of $115 million, up from $101 million year-over-year, driven by higher pricing, favorable product mix, and increased volumes. The company raised its 2026 adjusted EBITDA guidance to $380-$400 million and adjusted EPS outlook to $5-$5.45. NGVT stock has gained 26.3% over the past year and trades at a forward P/S multiple of 2.1, below the industry average of 2.45X.

Zacks Investment Research

Here's Why You Should Hold Onto Ingevity Stock for Now

Ingevity Corporation (NGVT) shares have gained 33.9% over the past year driven by portfolio transformation, strategic divestitures, and disciplined capital allocation. The company is focusing on high-return markets and targeting $300 million in share repurchases through 2027.

Zacks Investment Research

NGVT Stock Rallies 31% in a Year: What's Driving the Upside?

Ingevity Corporation (NGVT) shares have gained 30.6% over the past year, outperforming its industry. The company's portfolio optimization through divestitures and acquisitions, combined with improved cash flow generation and debt reduction to 2.5X leverage, has boosted investor confidence. NGVT is pursuing growth opportunities in PFAS filtration, biofuels applications, and capacity expansions while planning a $300 million share repurchase program through 2027.

Mentions NGVT

Headlines link to the publisher. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $NGVT · 0 threads

Sign in to post on $NGVT

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev